PIVENS: Vitamin E Superior to Placebo for Improving Nonalcoholic Steatohepatitis in Nondiabetic Patients
 |
|
Pioglitazone significantly improved certain features of nonalcoholic steatohepatitis, such as steatosis, lobular inflammation, and hepatocellular ballooning.
Format: Microsoft PowerPoint (.ppt) |
File size: 305 KB
| Date posted: 8/16/2010
Slide topics include:
|
Browse Slides by Date - Descending
Rifaximin Significantly Reduces Risk of Breakthrough HE and Hospitalization in Patients With Recurrent HE in Remission
 |
|
Rifaximin was significantly more effective than placebo at preventing additional episodes of HE over a 6-month period among patients of whom the majority (> 90%) also received concomitant lactulose treatment.
Format: Microsoft PowerPoint (.ppt) |
File size: 460 KB
| Date posted: 8/12/2010
Slide topics include:
|
Tenofovir Monotherapy Effective in HBV-Infected Patients With Previous Lamivudine, Less Effective in Those With Adefovir Resistance
 |
|
Tenofovir well tolerated in patients with previous nucleos(t)ide analogue failure.
Format: Microsoft PowerPoint (.ppt) |
File size: 266 KB
| Date posted: 8/12/2010
Slide topics include:
|
Serum HBsAg Significantly Decreased From Baseline to 1 Year During Entecavir Treatment in HBeAg-Positive Patients With Chronic Hepatitis B
 |
|
Decline in HBsAg correlated with decline in HBV DNA through 1 year of entecavir treatment.
Format: Microsoft PowerPoint (.ppt) |
File size: 339 KB
| Date posted: 8/12/2010
Slide topics include:
|
End-of-Treatment Response to Peginterferon alfa-2b Plus Lamivudine Durable out to 5 Years Posttreatment in Asian HBeAg-Positive Patients With Chronic Hepatitis B
 |
|
Virologic response at end of treatment found to be strongest independent predictor of SVR at 5 years posttreatment.
Format: Microsoft PowerPoint (.ppt) |
File size: 469 KB
| Date posted: 8/12/2010
Slide topics include:
|
Lower Relapse Rates When Treatment Extended From 48 to 72 Weeks in Genotype 1/4 HCV Patients With Slow Virologic Response to Peginterferon/Ribavirin
 |
|
SVR rates comparable between groups due to higher rate of voluntary treatment cessation after Week 48 in patients randomized to 72 weeks of treatment.
Format: Microsoft PowerPoint (.ppt) |
File size: 604 KB
| Date posted: 8/12/2010
Slide topics include:
|
Hepatic Expression of Interferon-Stimulated Genes Linked to IL28B Genetic Variation and Response to Peginterferon/Ribavirin in Chronic Hepatitis C
 |
|
Treatment nonresponse strongly associated with upregulation of interferon-stimulated genes before treatment initiation.
Format: Microsoft PowerPoint (.ppt) |
File size: 449 KB
| Date posted: 8/3/2010
Slide topics include:
|
PROVE3: Addition of Telaprevir to Peginterferon/Ribavirin Significantly Improves SVR Among Genotype 1 HCV Patients Who Failed Previous Peginterferon/Ribavirin Regimen
 |
|
High SVR rates observed in both previous relapsers and nonresponders, although rates higher in previous relapsers.
Format: Microsoft PowerPoint (.ppt) |
File size: 453 KB
| Date posted: 8/3/2010
Slide topics include:
|
Cultural Barriers in HBV Management
 |
|
A concise slideset detailing potential cultural barriers to screening and treatment among Asian Americans.
Format: Microsoft PowerPoint (.ppt) |
File size: 388 KB
| Date posted: 7/29/2010
Slide topics include:
|
Slideset: Keeping the Core: Assessing the Role of Pegylated Interferons and Emerging Novel Interferons in HCV Treatment
 |
|
Peter Ferenci, MD; Michael P. Manns, MD; and David R. Nelson, MD; discuss the safety and efficacy of approved and investigational interferons and their potential future role with direct-acting antivirals.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.99 MB
| Date posted: 6/7/2010
Slide topics include:
|
Slideset: Staying the Course: Patient Adherence Strategies in the Era of New Frontline HBV Therapies
 |
|
Robert G. Gish, MD, highlights the challenges for maintaining adherence in hepatitis B patients, and strategies for overcoming these barriers.
Format: Microsoft PowerPoint (.ppt) |
File size: 2.00 MB
| Date posted: 5/12/2010
Slide topics include:
|
|
Use the following filters to quickly browse and download slides for your talks
Browse slides by:
All Slides by Date (242)
Program Type
Topic
Featured Content
Strategies for optimizing treatment adherence in patients receiving HBV therapy.
Efficacy and safety of current HCV treatments and ongoing role in future HCV regimens.
Get Capsule Summaries, audio Expert Highlights, and a slideset from Vienna.
|
|